Amid rising scrutiny of the ties between patient charities and drug makers, a new study finds that nearly all of the programs run by the six largest organizations failed to provide assistance to people without insurance and were also more likely to cover expensive brand-name medicines than generics.

The study found that of 274 different disease-specific programs run by the charities in 2018, 267 programs — or a whopping 97% — required insurance coverage for eligibility. Meanwhile, brand-name drugs that cost more than $10,000 for each Medicare beneficiary in 2016 were three times more frequently covered by charities than generics.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy